SEC Stock Data Quick Answer Astera Labs, Inc. reported Total Assets of $1.53 billion for fiscal year 2025. Astera Labs, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $1.53B +45.3% 2024 $1.05B +437.2% 2023 $196.29M — Quarterly Total Assets Quarter Ending Total Assets YoY QoQ September 30, 2025 $1.40B +42.5% +10.2% June 30, … Read more
Quick Answer Astera Labs, Inc. reported Diluted EPS of $1.22 per share for fiscal year 2025. Astera Labs, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 $1.22 +290.6% 2024 -$0.64 +9.9% 2023 -$0.71 +58.5% 2022 -$1.71 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ September 30, 2025 $0.50 … Read more
Quick Answer Astera Labs, Inc. reported Net Income of $219.13 million for fiscal year 2025. Astera Labs, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 $219.13M +362.7% 2024 -$83.42M -217.7% 2023 -$26.26M +55.0% 2022 -$58.34M — Quarterly Net Income Quarter Ending Net Income YoY QoQ September 30, 2025 $91.11M +1300.0% … Read more
Quick Answer Astera Labs, Inc. reported Revenue (ASC 606) of $852.52 million for fiscal year 2025. Astera Labs, Inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $852.52M +115.1% 2024 $396.29M +242.2% 2023 $115.79M +45.0% 2022 $79.87M — Quarterly Revenue (ASC 606) Quarter Ending Revenue (ASC 606) YoY QoQ … Read more
Quick Answer Astera Labs, Inc. reported Total Revenue of $852.52 million for fiscal year 2025. Astera Labs, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $852.52M +115.1% 2024 $396.29M +242.2% 2023 $115.79M +45.0% 2022 $79.87M — Quarterly Total Revenue Quarter Ending Total Revenue YoY QoQ September 30, 2025 $230.57M +103.9% … Read more
Quick Answer Astera Labs, Inc. reported Total Revenue of $852.52 million for fiscal year 2025. Astera Labs, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 Total Revenue $852.52M+115.1% $396.29M+242.2% $115.79M+45.0% $79.87M — Revenue (ASC 606) $852.52M+115.1% $396.29M+242.2% $115.79M+45.0% $79.87M — Net Income $219.13M+362.7% -$83.42M-217.7% -$26.26M+55.0% -$58.34M — Diluted EPS $1.22+290.6% -$0.64+9.9% … Read more
Quick Answer Akari Therapeutics Plc reported Shares Outstanding of 90.54 billion shares for fiscal year 2025. Akari Therapeutics Plc Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 90.54B +70.2% 2024 53.19B +301.9% 2023 13.23B +77.8% 2022 7.44B +56.4% 2021 4.76B +23.7% 2020 3.85B +71.3% 2019 2.25B +719685.0% 2018 312,019 -100.0% 2017 … Read more
Quick Answer Akari Therapeutics Plc reported Operating Income of -$17.27 million for fiscal year 2025. Akari Therapeutics Plc Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$17.27M +20.2% 2024 -$21.64M -28.8% 2023 -$16.81M +27.2% 2022 -$23.09M -34.1% 2021 -$17.21M +4.3% 2020 -$17.98M -6.0% 2019 -$16.96M +18.4% 2018 -$20.79M +45.0% 2017 -$37.78M … Read more
Quick Answer Akari Therapeutics Plc reported R&D Expense of $2.81 million for fiscal year 2025. Akari Therapeutics Plc R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $2.81M -59.7% 2024 $6.98M +28.1% 2023 $5.45M -43.0% 2022 $9.56M +4.7% 2021 $9.13M +3.6% 2020 $8.82M +0.9% 2019 $8.74M -25.9% 2018 $11.80M -49.3% 2017 $23.29M … Read more
Quick Answer Akari Therapeutics Plc reported Stockholders Equity of $28.33 million for fiscal year 2025. Akari Therapeutics Plc Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $28.33M +27.4% 2024 $22.23M +9807.0% 2023 -$229.0K -112.8% 2022 $1.79M -67.8% 2021 $5.55M -40.8% 2020 $9.38M +35.1% 2020 $6.95M +16.6% 2020 $5.96M +82.3% 2020 $3.27M … Read more